Pharmaceutisch weekblad

, Volume 3, Issue 1, pp 484–490 | Cite as




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahlmark, G., enH. Saetre (1976)Eur. J. Clin. Pharmacology 10, 77–83.CrossRefGoogle Scholar
  2. Ahlmark, G., H. Saetre enM. Korsgen (1974)Lancet II, 1563.CrossRefGoogle Scholar
  3. Andersen, M. P., P. Bechsgaard, J. Frederiksen e.a. (1979)Lancet II, 865–867.CrossRefGoogle Scholar
  4. Balcon, R., D. E. Jewitt, J. P. H. Davies enS. Oram (1966)Lancet II, 917–920.CrossRefGoogle Scholar
  5. Berglund, G. L., L. Wilhelmsen, R. Sannerstedt e.a. (1978)Lancet I, 1–5.CrossRefGoogle Scholar
  6. Clausen, J., M. Felsby, F. S. Jürgensen e.a. (1966)Lancet II, 920–924.CrossRefGoogle Scholar
  7. Dahlstrom, U., U. Berglund enE. Karlsson (1980)Acta Med. Scand. 207, 167–171.CrossRefPubMedGoogle Scholar
  8. Green, K. G. (1977)Brit. Med. J. 2, 419–421.CrossRefGoogle Scholar
  9. Green, K. G., D. A. Chamberlain, R. M. Fulton e.a. (1975)Brit. Med. J. 3, 735–740.CrossRefGoogle Scholar
  10. Lie, K. I., H. J. Wellens, F. J. van Capelle enD. Durrer (1974)New Engl. J. Med. 291, 1324–1329.CrossRefPubMedGoogle Scholar
  11. Maroko, P. R., J. K. Kjekshus, B. E. Sobel, e.a. (1971)Circulation 43, 67–82.CrossRefPubMedGoogle Scholar
  12. Maroko, P. R., enD. M. Davidson (1980)Triangle I, 19–25.Google Scholar
  13. Medical Letter (1979)25, 101.Google Scholar
  14. Norris, R. M., D. E. Caughey enP. J. Scott (1968)Brit. Med. J. 2, 398–400.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Singh, B. N. (1978)Drugs 15, 218–225.CrossRefPubMedGoogle Scholar
  16. Stephen, S. A. (1966)Lancet II, 1435–1437.Google Scholar
  17. Stewart, J. M. G. (1976)Clin. Sci. Molecular Medicines 51, 509.Google Scholar
  18. Vedin, J. A., C. Wilhelmsson, G. Tibblin e.a. (1975)Acta Med. Scand. Suppl. 575, 7–40.Google Scholar
  19. Wilcox, R. G., J. M. Roland, D. C. Banks e.a. (1980a)Brit. Med. J. 280, 885–888.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Wilcox, R. G., J. M. Rowley, J. R. Hampton enJ. R. A. Mitchell (1980b)Lancet II, 765–769.CrossRefGoogle Scholar
  21. Wilhelmsson, C., L. Wilhelmsen, J. A. Vedin e.a. (1974)Lancet II, 1157–1160.CrossRefGoogle Scholar
  22. Yusuf, S., D. Ramsdale, R. Peto, e.a. (1980)Lancet II, 273–276.CrossRefGoogle Scholar
  23. Zainal, N., J. D. S. Carmichael, J. W. Griffiths e.a. (1977)Lancet II, 887–889.CrossRefGoogle Scholar


  1. Ali, M., e.a. (1980) Plasma acetylsalicylate and salicylate and platelet cyclo-oxygenase activity following plain and enteric-coated aspirin.Stroke 11, 9.CrossRefPubMedGoogle Scholar
  2. Dyken, M. L. (1979) Assessment of the role of antiplatelet aggregating agents in transient ischemic attacks, stroke and death.Stroke 10, 602.Google Scholar
  3. McDowell, F. H., C. H. Millikan enM. Goldstein.(1980) Treatment of impending stroke.Stroke 11, 1.CrossRefPubMedGoogle Scholar
  4. Medical Letter (1980) Aspirin for transient ischemic attacks.Stroke 11, 71.Google Scholar
  5. Olsson, J. E., e.a. (1980) Anticoagulant as antiplatelet therapy as prophylactic against cerebral infarction in transient ischemic attacks.Stroke 11, 4.CrossRefPubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1981

Personalised recommendations